Clinical trial · Interventional
Transplantation for Patients With Chronic Lymphocytic Leukemia
Autologous and Allogeneic Peripheral Blood Progenitor (PBPC) Transplantation for Patients With Chronic Lymphocytic Leukemia
NCT00186303CI-TRIAL-00008673completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the role of high dose therapy and autologous or allogeneic hematopoietic cell transplantation for the treatment of chronic lymphocytic leukemia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia, Lymphocytic, Chronic | Leukemia | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ablative allogeneic hematopoietic cell transplant | Procedure | — | UNRESOLVED |
| high dose chemotherapy then autologous hematopoietic cell transplant | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Efficacy
Secondary outcomes (3)
- measure
- Feasibility
- measure
- Toxicity
- measure
- olymerase Chain Reaction (PCR) for minimal residual disease
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria:- adequate organ function * normal bone marrow cytogenetics Exclusion Criteria:- active CNS disease * For autologous patients more than 30% bone marrow involvement
References
Publications (0)
Data not yet available
No reference posted for this study.